MZT Matritech,

Matritech (AMEX:MZT) announced today that it will release its second quarter 2007 earnings results before market opening on July 31, 2007. The company has scheduled a conference call at 8:30 a.m. (ET) that day to discuss the results and provide a company update. The call will be webcast and can be accessed on the Matritech web site at www.matritech.com. Conference Call Dial-in Number To access the conference call by phone, the dial-in number in the United States is 800-591-6945. The International number is 617-614-4911. The participant pass code is 18241894. The webcast will also be distributed over CCBN's Investor Distribution Network to both institutional and individual investors. About Matritech Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22� Test Kit and NMP22� BladderChek� Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech�s patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company�s goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com. Statement under the Private Securities Litigation Reform Act Any forward-looking statements in this press release including those related to the Company's expectations regarding future sales of the Company�s products, sales in specific target markets, future products under development by the Company or third parties, and business prospects are subject to a number of risks and uncertainties, many of which are beyond the Company�s control. Please refer to the risk factors detailed in the Company�s periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company�s expectations for its products or future financial performance will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.